Drug intelligence / Profile preview

MM020

Development stage: Preclinical
Lead developer: Mucommune
Modality: Gene Editing → Gene Therapies
Administration: Oral

Overview

MM020 is an investigational therapeutic candidate currently in the discovery phase of development by Mucommune. The program utilizes an in vivo cell engineering approach, a modality designed to genetically or functionally modify specific cell populations directly within the patient's body. While the specific biological targets and therapeutic indications for MM020 have not yet been disclosed, the platform likely leverages Mucommune's expertise in mucosal immunology and engineered delivery systems to address unmet medical needs.

Beyond the preview

Go deeper on MM020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MM020.

Explore the full profile